8-K
filed March 6, 2023, 6:59 PM ET
ticker ANIK
CIK 0000898437
earnings
confidence high
sentiment neutral
materiality 0.70
Anika Q4 revenue up 11% to $39.6M; net loss $4.9M; FY2023 guidance $158-163M
Anika Therapeutics, Inc.
- Q4 revenue $39.6M (+11% YoY); OA Pain Mgmt $23.7M (+20%), Joint Preservation $14.3M (+8%).
- Q4 net loss ($4.9M) or ($0.34) per share; adjusted net loss ($3.0M) or ($0.21) per share.
- Full year 2022 revenue $156.2M (+6%); net loss ($14.9M) vs net income $4.1M in 2021.
- FY2023 revenue guidance $158-163M (1-4% growth); OA Pain Mgmt $93.5-96M, Joint Preservation $55.5-58M.
- Hyalofast Phase III trial 199/200 enrolled; Cingal engaging FDA; RevoMotion limited release initiated.
Key facts
Extracted from this filing and checked against the source text.
Earnings Releases
SEC 8-K Item 2.02
confidence 0.95
Anika Therapeutics, Inc. reported the fourth quarter and year ended December 31, 2022 results: revenue $39.6 million, net income ($4.9) million, EPS ($0.34) per share.
- Period
- the fourth quarter and year ended December 31, 2022
- Revenue
- $39.6 million
- Net income
- ($4.9) million
- EPS
- ($0.34) per share
- Result
- reported results
Exact text from the filing
Revenue in the fourth quarter of 2022 was $39.6 million, up 11% compared with $35.8 million in the fourth quarter of 2021.
View on SEC.gov
Earnings Releases
SEC 8-K Item 2.02
confidence 0.95
Anika Therapeutics, Inc. reported fiscal year ended December 31, 2022 results: net income ($14.9) million, EPS ($1.02) per share.
- Period
- fiscal year ended December 31, 2022
- Net income
- ($14.9) million
- EPS
- ($1.02) per share
- Result
- reported results
Exact text from the filing
Revenue for fiscal 2022 increased 6% to $156.2 million, compared with $147.8 million in 2021
View on SEC.gov
Earnings Releases
SEC 8-K Item 2.02
confidence 0.95
Anika Therapeutics, Inc. reported fiscal year ended December 31, 2022 results: net income ($14.9) million, EPS ($1.02) per share.
- Period
- fiscal year ended December 31, 2022
- Net income
- ($14.9) million
- EPS
- ($1.02) per share
- Result
- reported results
Exact text from the filing
Net loss was ($14.9) million, or ($1.02) per share, compared to net income of $4.1 million, or $0.28 per diluted share, in 2021.
View on SEC.gov
Earnings Releases
SEC 8-K Item 2.02
confidence 0.95
Anika Therapeutics, Inc. reported the fourth quarter ended December 31, 2022 results: net income ($4.9) million, EPS ($0.34) per share.
- Period
- the fourth quarter ended December 31, 2022
- Net income
- ($4.9) million
- EPS
- ($0.34) per share
- Result
- reported results
Exact text from the filing
Net loss was ($4.9) million, or ($0.34) per share, compared to net loss of ($5.8) million, or ($0.40) per share, in the prior year period.
View on SEC.gov
This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice.
See methodology for how this pipeline works.